2-[4-amino-5-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-(ethylamino)cyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[4-amino-5-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-(ethylamino)cyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
• 化学式: C₂₁H₄₁N₅O₆
• 分子量: 459.6
• InChiKey: LWOBMQXDBZAZPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  180
• 氢给体数：
  7
• 氢受体数：
  11

文献信息

• COMPOSITIONS OF MULTICATIONIC DRUGS FOR REDUCING INTERACTIONS WITH POLYANIONIC BIOMOLECULES AND METHODS OF USE THEREOF
  申请人：Insmed Incorporated

  公开号：US20140248335A1

  公开（公告）日：2014-09-04

  The present invention relates, in part, to a composition comprising a multicationic drug and an organic multianion. In some embodiments, the multicationic drug is enclosed within a carrier. In some embodiments, the carrier is a liposome. In some embodiments, the multicationic drug and organic multianion are enclosed within a carrier, while in other embodiments, the multicationic drug is enclosed within the carrier and the organic multianion is outside the carrier. The present invention also relates, in part, to a method of treating a subject for pulmonary distress comprising administering to a subject in need thereof the aforementioned composition.